Imugene Share Price and Company Fundamentals

-0.010 (-2.778%)
52 week
0.092 - 0.625

Last traded: Last Friday at 5:10 AM

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Key Metrics

PE ratio


PB ratio


Dividend yield



Market cap


Enterprise value


Company profile

Primary activities.
Industry / SectorBiotechnology / Healthcare
Mailing address37 Bligh Street SUITE 804 LEVEL 8 Sydney NSW 2000 Australia
Phone / Fax /


Imugene does not pay dividends.

Company Executives

As of Jan 2022, following are the company executives and directors listed on Imugene.

NameTitleAgeTotal Pay
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICDExec. Chairman65369.32k
Ms. Leslie ChongCEO, MD & Exec. Director719.13k
Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D.Chief Technology Officer328.88k
Dr. Rita Laeufle M.D., Ph.D.Chief Medical Officer681.31k
Mr. Phillip Allen HainsCFO & Joint Company Sec.62
Dr. Anthony GoodSr. VP of Clinical Research
Dr. Monil Shah M.B.A., Pharm.D.Chief Bus. Officer
Ms. Ursula McCurrySr. VP of Clinical Operations
Mr. Nathan Jong C.A.Joint Company Sec.

Profitability and management effectiveness

Profit margin


Operating margin


Return on assets


Return on equity


Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Imugene is and its enterprise value is .

The IMU's stocks Beta value is 1.94 making it 94% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Imugene (IMU)

Imugene (ASX:IMU) Frequently Asked Questions

1. What is Imugene's Stock Symbol?

Imugene trades on ASX under the ticker symbol "IMU".

2. What is Imugene's stock price today?

One share of IMU stock can currently be purchased for approximately $0.35.

3. How can I contact Imugene?

Imugene's mailing address is 37 Bligh Street SUITE 804 LEVEL 8 Sydney NSW 2000 Australia. The company can be reached via phone at .

4. What is Imugene's official website?

The official website of Imugene is

5. Which share registry manages Imugene's stock?

Imugene's stock is managed by AUTOMIC REGISTRY SERVICES.